ReviewCurrent treatment options in oncology2024
Desmoid Tumors: Current Perspective and Treatment.
Review in Current treatment options in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Abnormal Presentation of an Intra-abdominal Desmoid Tumor in a Young, Healthy Male: A Case Report.Cureus · 2026Article
- Expert opinion document on the management of desmoid tumours in adult patients in Spain.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Spindle Cell Fibromatosis of the Breast: A Lesson in Malignancy Mimicry.Clinical case reports · 2026Article
- Abdominal Wall Desmoid Tumor Misdiagnosed as Schwannoma: A Case Report.Clinical case reports · 2026Article
- Gardner syndrome initially misdiagnosed as bilateral breast malignancy: a case report and literature review.Frontiers in oncology · 2026Article
- Breast Desmoid-Type Fibromatosis Mimicking Carcinoma on Imaging: A Case Report.Surgical case reports · 2026Article
- Cryoablation as a downsizing strategy enabling R0 resection in a giant mediastinal desmoid tumor: a case report.Mediastinum (Hong Kong, China) · 2026Article
- Multifocal Mesenteric Desmoid-Type Fibromatosis After Liver Transplantation: A Case Report.The American journal of case reports · 2025Article
- Exploring Clinical Studies and the FDA Adverse Event Reporting System (FAERS) Database for nirogacestat-related Adverse Events.Therapeutic innovation & regulatory science · 2025Article
- Surgical Resection and Abdominal Wall Reconstruction of a Rapidly Progressive Desmoid Tumor: A Case Report.Cureus · 2025Article
- The Desmoid Dilemma: Challenges and Opportunities in Assessing Tumor Burden and Therapeutic Response.Current oncology (Toronto, Ont.) · 2025Review
- Sporadic Desmoid-Type Fibromatosis of the Small Intestine Muscularis Propria: A Case Report.Cureus · 2025Article
- Case report: a case of pelvic retroperitoneal aggressive fibromatosis misdiagnosed as ovarian cystadenoma.Internal and emergency medicine · 2025Article
- An intra-abdominal desmoid tumour: Case report.International journal of surgery case reports · 2025Article
- Precision oncology: The role of minimally-invasive ablation therapy in the management of solid organ tumors.World journal of radiology · 2025Review
- Case Report: Gefitinib in EGFR 19del recurrent aggressive fibromatosis.Frontiers in oncology · 2025Article
- Retroperitoneal invasive fibromatosis after laparoscopic radical resection of colon cancer: a case report and literature review.Frontiers in oncology · 2025Article
- How Arterial Embolization Is Transforming Treatment of Oncologic and Degenerative Musculoskeletal Disease.Current oncology (Toronto, Ont.) · 2024Review
- Secondary Osteosarcoma After Carbon-Ion Radiotherapy for Desmoid-Type Fibromatosis: A Case Report.Cancer reports (Hoboken, N.J.) · 2024Article
- Hemorrhagic Shock Caused by an Aggressive Fibromatosis in the Gastropancreatic Region: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementDesmoid tumors are rare tumors with a tendency to infiltrate locally. The lack of a standard treatment approach makes choosing the most appropriate treatment for patients challenging. Most experts recommend watchful observation for asymptomatic patients as spontaneous regression of tumor is observed in up to 20% of patients. Upfront resection of the desmoid tumor has fallen out of favor due to high morbidity and high relapse rates associated with the tumor. Systemic therapy has evolved over several decades. Where chemotherapy, hormonal therapy, and non-steroidal anti-inflammatory drugs were used over the last several decades, tyrosine kinase inhibitors came to the forefront within the last decade. Most recently, gamma-secretase inhibitors have shown significant clinical benefit in patients with desmoid tumors, bringing forth an entirely new mechanistic approach. Several Wnt pathway inhibitors are also under development. Invasive approaches like cryoablation have also shown clinical benefit in patients with extra-abdominal desmoid tumors in recent years. The recent approval of nirogacestat has ushered in a new era of treatment for patients diagnosed with desmoid tumors. Several new molecules are expected to be approved over the coming years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.